Clinical Scorecard: Identifying the Underlying Factors of Chronic Diarrhea

At a Glance

Key Highlights

• WM is characterized by IgM monoclonal protein and ≥10% bone marrow infiltration by clonal lymphoplasmacytic cells.
• Intestinal lymphangiectasia occurs in 1–3% of WM cases, causing gastrointestinal symptoms including chronic diarrhea.
• Treatment with rituximab, cyclophosphamide, and dexamethasone (RCD regimen) can lead to symptom resolution and lesion regression.

Guideline-Based Recommendations

Diagnosis

• Perform bone marrow examination to identify clonal lymphoplasmacytic infiltration and IgM expression.
• Use immunophenotyping to detect markers CD19, CD20, CD22, CD45 and absence of CD5 and CD23.
• Identify MYD88 L265P mutation to support diagnosis of WM.
• Conduct endoscopic evaluation (gastroscopy, colonoscopy, capsule endoscopy) to detect intestinal lesions.
• Histological examination with D2-40 immunohistochemistry to confirm dilated lymphatic vessels in intestinal biopsies.

Management

• Administer RCD chemotherapy regimen (rituximab, cyclophosphamide, dexamethasone) for WM with intestinal involvement.
• Monitor IgM levels to assess treatment response.
• Address nutritional status and manage symptoms such as diarrhea and abdominal distension.

Monitoring & Follow-up

• Regular follow-up endoscopy to evaluate regression of intestinal lesions.
• Monitor hematologic parameters including hemoglobin and serum protein levels.
• Assess clinical symptoms and nutritional status periodically.

Risks

• Potential complications include hyperviscosity syndrome, anemia, thrombocytopenia, hepatosplenomegaly, and lymphadenopathy.
• Intestinal lymphangiectasia may lead to malabsorption and severe weight loss if untreated.

Patient & Prescribing Data

Adults diagnosed with Waldenström’s macroglobulinaemia presenting with gastrointestinal symptoms

Partial response to RCD chemotherapy is associated with decreased IgM levels, symptom resolution, and improved nutritional status.

Clinical Best Practices

• Consider WM in differential diagnosis of chronic diarrhea with weight loss and elevated IgM.
• Use a multidisciplinary approach involving hematology and gastroenterology for diagnosis and management.
• Employ comprehensive diagnostic workup including laboratory, imaging, endoscopy, histology, and molecular testing.
• Initiate appropriate chemotherapy promptly to prevent progression and complications.
• Monitor treatment response with clinical, laboratory, and endoscopic assessments.

References

• Waldenström’s macroglobulinaemia clinical features and management
• Intestinal lymphangiectasia in Waldenström’s macroglobulinaemia
• Pathogenesis of IgM-phospholipid deposition in WM